Diroximel fumarate

Diroximel fumarate
Clinical data
Trade names	Vumerity
Other names	ALKS-8700
AHFS/Drugs.com	Monograph
MedlinePlus	a620002
License data	US DailyMed: Diroximel_fumarate;
Routes of; administration	By mouth
ATC code	None;
Legal status
Legal status	US: ℞-only [1];
Identifiers
CAS Number	1577222-14-0;
PubChem CID	73330464;
DrugBank	DB14783;
ChemSpider	57423290;
UNII	K0N0Z40J3W;
KEGG	D11154;
ChEMBL	ChEMBL3989944;
Chemical and physical data
Formula	C11H13NO6
Molar mass	255.226 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC(=O)C=CC(=O)OCCN1C(=O)CCC1=O;
	InChI InChI=1S/C11H13NO6/c1-17-10(15)4-5-11(16)18-7-6-12-8(13)2-3-9(12)14/h4-5H,2-3,6-7H2,1H3/b5-4+; Key:YIMYDTCOUQIDMT-SNAWJCMRSA-N;

Diroximel fumarate, sold under the brand name Vumerity, is a medication used for the treatment of relapsing forms of multiple sclerosis (MS).[1]

Diroximel fumarate was approved for medical use in the United States in October 2019.[2]

References

"Vumerity- diroximel fumarate capsule". DailyMed. Retrieved 1 February 2021.
"Drug Approval Package: Vumerity". U.S. Food and Drug Administration (FDA). 21 April 2020. Retrieved 1 February 2021.

External links

"Diroximel fumarate". Drug Information Portal. U.S. National Library of Medicine.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Vumerity_FDA_label-1] "Vumerity- diroximel fumarate capsule". DailyMed. Retrieved 1 February 2021.

[2] "Drug Approval Package: Vumerity". U.S. Food and Drug Administration (FDA). 21 April 2020. Retrieved 1 February 2021.